Anti-inflammatory treatment such as inhibition of the mammalian target of rapamycin pathway or genetic ablation of microRNA-33 attenuates inflammation and AAA (Li et al., 2017; Nakao et al., 2017), indicating that anti-inflammatory treatment should be the promising strategy for AAA treatment. This evidence concerns the gene MTOR and triple-A syndrome.